**Core tip:** Recent advances, using transgenic mice, in understanding cellular hierarchies in the intestinal epithelium have identified numerous cell populations which retain the ability to change their fate in response to injury. Here, these new studies are presented in the context of a discussion about what represents a relevant epithelial injury to understand "homeostatic regeneration". Experimental suggestions are proposed for validating animal findings to translate our current knowledge to better understand human intestinal epithelial maintenance.

INTRODUCTION
============

The intestinal lining is one of the most rapidly proliferating epithelia in humans. In the small intestine this single-cell thick structure is thrown into folds consisting of villi that protrude into the lumen and crypts that are embedded in the intestinal wall. The colonic epithelium is similar although lacks villi. At a histological level the small intestine and colon are also alike. In the small intestine the most prevalent cell type is the absorptive enterocyte and, in the colon, the colonocyte. Both organs also possess secretory goblet, enteroendocrine and tuft cells (Figure [1](#F1){ref-type="fig"}). The main cellular difference between the small intestine and colon is the presence of secretory Paneth cells. These long-lived secretory and niche cells are only found in the bottom of small intestinal crypts and rarely found in the normal colon. A functionally similar cell type, termed the deep crypt secretory cell, has however recently been shown to exist in colonic crypts\[[@B1],[@B2]\]. Both epithelia are highly proliferative and retain a remarkable ability for regeneration following injury. Homeostatic proliferation throughout the intestine takes place in the bottom of the crypts, being most active in the so-called transit amplifying zone -- an area directly above the crypt base. Differentiation occurs as cells migrate up the crypts onto either villi or the colonic mucosal plateau.

![Schematic of the arrangement of cells in the small intestine. CBC: Crypt base columnar cell; LRC: Label retaining cell.](WJG-25-3116-g001){#F1}

Over the last two decades the intestine has become an area of great interest in stem cell biology and is arguably the prototypical organ for the study of epithelial homeostasis and regeneration partly due to the unique structure of the crypt that facilitates ready quantification of stem cell clonogenicity. Following seminal findings using lineage tracing, of the clonogenic function of undifferentiated crypt cells during homeostasis, the concept of cellular plasticity has more recently been explored using contemporary *in vivo* techniques. Plasticity is defined as a change in cell fate in response to a stimulus. The results of these new studies have however led the field into a complex and confusing period where, on face value, it appears that almost any cell type in the intestinal epithelium can revert to a stem cell state during regeneration. In this opinion review I discuss both the important original and more recent studies and propose that whilst the findings are striking they may not be entirely relevant for our understanding of "homeostatic regeneration". Here, I define homeostatic regeneration as the cellular changes that occur during the response to injury classically occurring during mammalian life and commonly encountered pathologies.

Evidence for the existence of intestinal stem cells was first demonstrated in the 1970s by Cheng and Leblond who showed that after treating mice with tritiated thymidine, crypt base columnar cells (CBCs) developed labelled phagosomes following phagocytosis of nearby non-viable cells\[[@B3]\]. Subsequent tracing of these labelled phagosomes over time found they were inherited by all the differentiated cell types of the epithelium. These experiments proposed that stem cells present in the base of intestinal crypts could generate all the differentiated cell types of the intestinal epithelium. Following this, attention focussed on cells in the so-called +4 position that appeared both quiescent and undifferentiated -- a feature commonly found in stem cells in other organs\[[@B4]\]. The field however underwent a sea change in 2007 following the publication from Hans Clevers' laboratory demonstrating that *Lgr5* expression marked rapidly proliferating CBCs in the small intestine and colon which were capable of profound clonal capacity as shown using a lineage tracing technique in mice\[[@B5]\]. This highly elegant study provided the first direct proof that rapidly cycling Lgr5+ CBCs were the bona fide homeostatic stem cells of throughout the intestine. There then followed a period of intense debate about the nature of the +4 cell with several groups showing marker overlay of genes of interest with cells in this position also possessing stem cell capacity including *Bmi1*, *Hopx* and *mTert*\[[@B6]-[@B8]\]. Interestingly, like the original Barker et al\[[@B5]\] study, all three of these studies primarily used the location of promoter driven reporter expression to define the anatomical location of cells expressing the respective gene of interest. It is however unknown what degree of gene activity is required to drive reporter expression and this can be compounded by the introduction of *Cre* recombinase as a conditional activator of reporter expression as is often used in lineage tracing studies. Highlighting these issues, two separate studies of *Bmi1* expressing cells using different models; *Bmi1-CreER* and *Bmi1-GFP* (both knocked in at the endogenous locus) show different results with one study finding the cells to be stem cells and the other mature enteroendocrine cells\[[@B6],[@B9]\]. The Cre enzyme is also seen to possess apparent regional differences in expression when under the control of reportedly pan intestinal promoters; Cre is often found to have greater activity the more proximal in the intestinal tract making it hard to compare with stem cell behaviour in the distal small intestine and colon\[[@B10],[@B11]\]. Whether this is due to promoter, enzyme intrinsic or reporter differences is incompletely understood. These concerns can be compounded when a CreER system is used to drive conditional recombination. In this situation off-target effects of both tamoxifen and impaired stem cell function following activation of Cre have been reported by two separate studies\[[@B12],[@B13]\]. These important studies indicate that quantification of stem cell behaviour following tamoxifen driven Cre activation may not be accurate or representative of the true *in vivo* situation.

Tissue specific gene promoters can also have problems with both sensitivity and specificity for all cells on the crypt-villus axis. A comparison between two intestinal, reportedly pan-epithelial Cre models, *Villin-Cre* and *Ah-Cre* showed unexpected variation in the *Ah-Cre* driven recombination that failed to target a cell population that was capable of driving regeneration\[[@B14]\]. Previously the *Ah-Cre* model had been reported to induce recombination in all IECs other than terminally differentiated Paneth cells\[[@B10]\]. However, in the study by Parry et al\[[@B14]\] the authors found that *Ah-Cre* also failed to induce recombination in a non-Paneth cell putative reserve stem cell population. The implication of this work is that quantifying global clonal output using *Ah-Cre* driven reporters may not include all potentially clonogenic populations and erroneous conclusions could be drawn.

It is also unknown how long reporter proteins persist and are visible for, following cessation of their production. It is likely that different reporters have varying stability that could confound analysis if induced conditionally and thus temporally where expression may still be visualised in daughter cells that aren't expressing the mRNA of the gene of interest. This may lead to an assumption that reporter expression is directly correlated with gene expression which has not definitively be proven. Cells may also express low levels of the gene of interest and still possess the same functionality as those with high levels of expression (as the marker itself is unlikely to directly drive function) but low expressors may fail to be identified by reporter expression. Indeed, precisely these concerns were found valid when bulk gene expression comparisons were used to compare the transcriptome of CBC Lgr5+ cells with +4 located Bmi1+ cells suggesting that these cells are in reality one and the same and the +4 cell may well be *Lgr5* expressing\[[@B15]\]. Cumulatively, all these early studies certainly provide direct evidence that homeostatic stem cells exist at the base of the intestinal crypts but also demonstrate the clear difficulties in using transgenic mouse models to dissect subpopulations and functionality at a high level of detail.

Given the striking ability of the intestinal epithelium to regenerate, a natural progression of recent research focus has been to understand which cell populations are responsible for this behaviour. Theoretically there are two possible cell types responsible for regeneration; a distinct quiescent sub-population waiting to become activated when required or a population that has one role during homeostasis but that can revert to a stem-like state during injury *i.e*., plastic. The first named population found to have a role in regeneration were *Dll1* expressing crypt cells\[[@B16]\]. Using a combination of lineage tracing in combination with irradiation the Clevers group found that during homeostasis these cells were proliferating secretory progenitors but following irradiation and cell death they acquired stem cell capacity and were thus capable of regenerating the injured epithelium. The question of what the apparently quiescent +4 cell represented was further addressed by Doug Winton's group using a novel split-Cre mouse to conditionally genetically mark label-retaining cells (LRCs)\[[@B17]\]. Supporting the findings of the Clevers group this study found LRCs to be a slowly-cycling Paneth and enteroendocrine cell progenitor that similarly reverted to a stem cell-like fate during injury induced regeneration albeit at very low frequency - partly due to the complexities of the transgenic model employed.

Following the finding of plasticity in *Dll1* cells and LRCs, attention has focussed on whether other populations can perform similar functions. Indeed, it has now been shown that goblet cells, enteroendocrine cells, enterocytes and Paneth cells are all capable of contextually acquiring stem cell capacity\[[@B9],[@B18]-[@B28]\]. Analysis of these reports however shows wide variation in the types of injury models employed varying from relatively mild oral dextran sulfate sodium (DSS) that induces mucosal inflammation, to lethal whole-body irradiation (12Gy), making it difficult to compare results between studies (Table [1](#T1){ref-type="table"}). More recently it has also been shown that some secretory progenitor populations even during homeostasis may stochastically acquire stemness\[[@B22],[@B26],[@B28]\]. This bi-fated character of some secretory progenitors was originally demonstrated in 2004 where a small number of *Ngn3* enteroendocrine cell progenitors were also found to have clonal/stem cell capacity during homeostasis\[[@B29]\]. Whilst it is entirely plausible that there are a wide range of cell types capable of plasticity there are evidently those that cannot, as clone formation has never been found arising on villi even during classical injury induced regeneration. Schwitalla et al\[[@B30]\] have however demonstrated that aberrant elevated NF-kB signalling in apparently terminally differentiated enterocytes on the villi can cause dedifferentiation to a tumour-initiating *Lgr5+* status. This finding proposes that at the very least, if given a strong enough stimulus, even terminally differentiated villus-based enterocytes may acquire some stem cell characteristics.

###### 

Mouse injury models used for plasticity studies

  **Study**                   **Plastic cell identified**   **Injury model used**
  --------------------------- ----------------------------- -------------------------------------------
  Tian et al\[[@B18]\]        Bmi1+ cell                    DTR Lgr5+ ablation
  Roth et al\[[@B19]\]        Paneth cell                   12Gy radiation
  van Es et al\[[@B16]\]      Dll1+ cell                    6Gy radiation
  Buczacki et al\[[@B17]\]    Label-retaining cell          6Gy radiation, doxorubicin or hydroxyurea
  Asfaha et al\[[@B20]\]      Upper crypt progenitor        12Gy radiation +/- 5-Fluorouracil
  Tetteh et al\[[@B27]\]      Alpi1+ enterocyte             DTR Lgr5+ ablation
  Jadhav et al\[[@B9]\]       Goblet cell progenitors       DTR Lgr5+ ablation
  Yan et al\[[@B21]\]         Enteroendocrine cell          12Gy radiation
  Ishibashi et al\[[@B22]\]   Atoh1+ cell                   DSS (1.75%) for 5 d
  Nusse et al\[[@B23]\]       Lgr5- crypt cell              Parasite infection
  Schmitt et al\[[@B24]\]     Paneth cell                   DSS (3%) for 1 wk
  Tomic et al\[[@B26]\]       Atoh1+ cell                   6Gy radiation, AOM or 2% DSS
  Yu et al\[[@B25]\]          Lyz1+ Paneth cell             12Gy radiation
  Castillo et al\[[@B28]\]    Atoh1+ cell                   DSS (2.5%-3%) for 5 d

Cumulatively, these studies show widespread plasticity amongst almost every cell type described to-date in the murine intestinal epithelium however there are many inconsistencies between studies driven primarily from the technical issues related to ascribing identity and plasticity (Table [2](#T2){ref-type="table"}). It could also be argued that the apparent broadly found plasticity may not be relevant to advancing our understanding of what cell types are *actually* at play in humans during routine epithelial insult. It has been known for decades that cell types can be reprogrammed to different identities and this forms the fundamental basis of induced pluripotent stem cells (iPS) technology. In Waddington's classical model of the epigenetic landscape of differentiation it is therefore clear that cells can traverse between several deep valleys given the appropriate stimulus to ascend the elevations between\[[@B31]\]. Evidently, any cell type if pushed hard enough can de-differentiate or trans-differentiate but the question remains what represents a *physiological injury* and what cell types are involved in the subsequent "homeostatic regeneration"? It may well be the case that during different forms of injury such as that seen between Crohn's disease and ulcerative colitis varying cell types are mobilised *via* plasticity to the stem cell state to try and repair the damaged epithelium.

###### 

Concepts leading to difficulties in ascribing behaviour to cell types in the intestine

  ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  CreER and Tamoxifen                                              Toxicity
  Off-target effects                                               
  Incongruity between reporter expression and protein expression   Regional differences
  Chronicity of reporter stability                                 
  Reporter and mRNA expression differences                         
  Inconsistent injury models                                       Intestinal specific effects including incomplete cell type eradication *e.g*., diphtheria toxin mediated cell death
  Off-target whole body effects *e.g*., irradiation                
  Representative of "homeostatic regeneration"                     
  Different cell-type responses to different injuries              
  Laboratory differences                                           Microbiota
  Diet                                                             
  Area of intestine examined                                       
  Strain differences between laboratories due to inbreeding        
  ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------

How then can the field move forward to make meaningful in-roads into translating these previous animal findings to the benefit of patients? There are two areas that would seem ripe for development -- tools for lineage tracing in humans and better validated injury models in mice. Lineage tracing in mice is primarily performed through generating transgenic mouse strains which is clearly impossible in humans. There are however several new tools that could permit lineage tracing analysis in human tissue albeit by quantifying the clonal output of all potentially clonogenic cells. Two important recent reports have made use of next generation sequencing technology to identify clones through the quantification of somatically acquired mosaic mutations found in human and murine tissue\[[@B32],[@B33]\]. The advances now made in sequencing technologies enabling combined single cell DNA (scDNAseq) and RNA sequencing (scRNAseq) allow for similar sequencing approaches with higher coverage to uncover cellular hierarchies from human tissue in both disease and homeostasis.

Clonal marking in humans can also be performed by quantifying mitochondrial DNA (mtDNA) mutations through dual immunohistochemical (IHC) staining for the mitochondrially encoded enzyme cytochrome-c oxidase (CCO)\[[@B34]\]. Cells acquire mtDNA mutations infrequently and can be identified through this IHC technique as cumulatively more are acquired in the many mtDNA copies of the CCO gene *via* stochastic genetic drift. As the mutation is genetic and therefore heritable, the clonal output of cells acquiring these mutations can be quantified. More recently several new similarly working but genomic DNA (gDNA) encoded neutral IHC clonal marks have been described by the Winton laboratory\[[@B35]\]. Importantly, both CCO staining and the newer clonal marks allow the quantification of clonal behaviour in situ from human tissue. Using these techniques on matched sections of diseased and normal tissue allows an understanding, at the numerical level, of changes in behaviour such as seen in plasticity. Further, combining these lineage tracing approaches with scRNAseq could provide profound insights, like those described in the mouse, to understanding intestinal homeostasis and plasticity in humans.

CONCLUSION
==========

Finally, there is an urgent need to better define the cellular effects of common human intestinal epithelial injuries to identify appropriate murine model equivalents. The current use of multiple different forms of injury models which only bear a passing relationship to human disease in that there is some degree of cell death is far from ideal. The interplay between epithelial loss, stromal tissue, immune cells, vasculature and resident microbiota is highly complex and very likely inadequately modelled in our current simplistic models of injury performed on mice housed in clean animal facilities. Here, the opposite approach to that presented earlier could be used: Human studies into the precise cellular events occurring during various injuries could inform the development of better murine injury models. It would appear that the field is reaching the limitations of what can be achieved with current tools and models and in order to advance as rapidly as previously, new approaches are required that maximise on novel technologies and translationally relevant models.
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